Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
Ainos Inc. (NASDAQ:AIMD) announced its participation in a fireside chat with Water Tower Research on August 22, 2024, at 10:00 a.m. ET. Jack Lu, Director of Corporate Development, will present an overview of Ainos' business model, strategic priorities, and AI Nose technology platform. The discussion will cover lead pipeline products, including the low-dose IFN-α therapeutic VELDONA, and its potential in human and animal health.
The fireside chat will also address Ainos' recent earnings and financial position. This listen-only event is open for registration, and a replay will be available on the company's investor relations website. Ainos is a diversified healthcare company focusing on AI-powered point-of-care testing (POCT) and VELDONA therapeutics.
Ainos Inc. (NASDAQ:AIMD) ha annunciato la sua partecipazione a una chiacchierata informale con Water Tower Research il 22 agosto 2024, alle 10:00 ora ET. Jack Lu, Direttore dello Sviluppo Aziendale, presenterà una panoramica del modello di business di Ainos, delle priorità strategiche e della piattaforma tecnologica AI Nose. La discussione affronterà i prodotti della pipeline principali, tra cui il terapeutico a bassa dose IFN-α VELDONA, e il suo potenziale nella salute umana e animale.
La chiacchierata informale tratterà anche degli utili recenti di Ainos e della sua posizione finanziaria. Questo evento, accessibile solo in ascolto, è aperto alla registrazione, e una registrazione sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda. Ainos è un azienda sanitaria diversificata che si concentra sul testing point-of-care (POCT) potenziato dall'IA e sulle terapie VELDONA.
Ainos Inc. (NASDAQ:AIMD) anunció su participación en una charla informal con Water Tower Research el 22 de agosto de 2024, a las 10:00 a.m. ET. Jack Lu, Director de Desarrollo Corporativo, presentará un resumen del modelo de negocio de Ainos, sus prioridades estratégicas y la plataforma tecnológica AI Nose. La discusión cubrirá los productos de la cartera, incluyendo el terapéutico VELDONA de IFN-α en dosis baja, y su potencial en la salud humana y animal.
La charla informal también abordará las ganancias recientes y la posición financiera de Ainos. Este evento, que solo se puede escuchar, está abierto para la inscripción, y una repetición estará disponible en el sitio web de relaciones con inversores de la compañía. Ainos es una empresa de atención médica diversificada que se enfoca en pruebas en el punto de atención (POCT) impulsadas por IA y terapias VELDONA.
Ainos Inc. (NASDAQ:AIMD)는 2024년 8월 22일 오전 10:00 ET에 Water Tower Research와의 간담회에 참여한다고 발표했습니다. 기업 개발 이사인 Jack Lu가 Ainos의 비즈니스 모델, 전략적 우선순위 및 AI Nose 기술 플랫폼에 대한 개요를 발표할 예정입니다. 토의에서는 저용량 IFN-α 치료제 VELDONA를 포함한 제품 파이프라인에 대해 다룰 것이며, 이는 인간 및 동물 건강에 대한 잠재력을 보유하고 있습니다.
간담회에서는 Ainos의 최근 실적 및 재무 상태도 언급될 것입니다. 이 오디오 전용 이벤트는 등록이 가능하며, 재생 링크는 회사의 투자자 관계 웹사이트에서 제공될 예정입니다. Ainos는 다양화된 헬스케어 기업으로 AI 기반 포인트 오브 케어 검사(POCT) 및 VELDONA 치료제에 주력하고 있습니다.
Ainos Inc. (NASDAQ:AIMD) a annoncé sa participation à une discussion informelle avec Water Tower Research le 22 août 2024 à 10h00 ET. Jack Lu, directeur du développement commercial, présentera un aperçu du modèle commercial d'Ainos, des priorités stratégiques et de la plateforme technologique AI Nose. La discussion portera sur les produits clés de la pipeline, y compris le thérapeutique VELDONA à faible dose d'IFN-α, et son potentiel en santé humaine et animale.
La discussion informelle traitera également des résultats récents d'Ainos et de sa position financière. Cet événement, uniquement accessible en écoute, est ouvert à l'inscription, et un enregistrement sera disponible sur le site web des relations avec les investisseurs de l'entreprise. Ainos est une entreprise de santé diversifiée qui se concentre sur les tests au point de service (POCT) alimentés par l'IA et les thérapies VELDONA.
Ainos Inc. (NASDAQ:AIMD) hat die Teilnahme an einem Fireside-Chat mit Water Tower Research am 22. August 2024 um 10:00 Uhr ET angekündigt. Jack Lu, Direktor für Unternehmensentwicklung, wird einen Überblick über das Geschäftsmodell von Ainos, strategische Prioritäten und die AI Nose-Technologieplattform präsentieren. Die Diskussion wird die Schlüsselprodukte der Pipeline, einschließlich des niedrigdosen IFN-α Therapeutik VELDONA, und dessen Potenzial in der menschlichen und tierischen Gesundheit abdecken.
Der Fireside-Chat wird auch die aktuellen Erträge und die finanzielle Lage von Ainos thematisieren. Diese nur zum Zuhören zugängliche Veranstaltung ist zur Registrierung geöffnet, und eine Wiederholung wird auf der Investor-Relations-Website des Unternehmens verfügbar sein. Ainos ist ein diversifiziertes Gesundheitsunternehmen, das sich auf KI-gestützte Point-of-Care-Tests (POCT) und VELDONA Therapeutika konzentriert.
- None.
- None.
SAN DIEGO, CA / ACCESSWIRE / August 12, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that it will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") on Thursday, August 22, 2024 at 10:00 a.m. ET.
Mr. Jack Lu, Ainos' Director of Corporate Development, will provide an overview of the Company's business model, strategic priorities, and innovative AI Nose technology platform. He will also discuss lead pipeline products, including the low-dose IFN-α therapeutic VELDONA, and its opportunities in human and animal health, as well as Ainos' latest earnings and financial standing.
To register for this listen-only event, please visit:
Fireside Chat Registration Link
The replay of the fireside chat will be available under "Events" in the Ainos' investor relations website at https://ir.ainos.com/
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.
The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.
Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products ; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Investor Relations Contact
Feifei Shen
Email: IR@ainos.com
SOURCE: Ainos
View the original press release on accesswire.com
FAQ
When is Ainos (AIMD) participating in the Water Tower Research fireside chat?
What topics will be discussed in Ainos' (AIMD) fireside chat?
Who will represent Ainos (AIMD) in the Water Tower Research fireside chat?
How can investors access the Ainos (AIMD) fireside chat?
What are Ainos' (AIMD) main focus areas in healthcare?
